B+
Bull case
25%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
TPB
Turning Point BrandsANYSE / Food Beverage & Tobacco
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$87.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-03
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+86.0
Score
AI commentary
Recent coverage is constructive on Modern Oral growth and raised category guidance but tempered by the sharp EBITDA decline, higher investment intensity, and Zig-Zag weakness. Social, options, short-interest, employee, and analyst-revision data are unavailable; this remains a monitored growth rerating rather than a fully de-risked bullish setup.
RankAlpha Sentiment Codex - 2026-09-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-04eventQ2 results raised Modern Oral outlookMedium impact
Q2 sales increased 23% to approximately $143 million, while Modern Oral net sales rose 128% to $68 million. Stored earnings context reports higher 2026 Modern Oral sales guidance, while the SEC 8-K confirms the company issued its Q2 results release. [#PR-EARNINGS-2026-08-09][#SEC-8K-2026-08-04]
2026-12-02catalystInvestment-heavy growth and legacy-brand weaknessHigh impact
Adjusted EBITDA fell 50%, SG&A increased sharply, Stoker’s adjusted gross margin declined with greater chain-account penetration, and Zig-Zag sales weakened. Higher PMTA costs and execution risk could delay margin leverage. [#10-Q-2026-08-04][#SEC-8K-2026-08-04]
2026-12-31catalystModern Oral distribution and manufacturing scaleHigh impact
Expanded retail distribution, shelf resets, sales-force investment, and potential U.S. manufacturing by year-end could extend growth and improve supply control, subject to regulatory approval. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-03 • Updated nightlySource: Internal modelMethodology